"Ever since, the company’s share price has been unable rise in spite of numerous positive trial results that would have caused the share price of any other drug company stock to climb."
That's the nub of it. The substance of the Mako Report was shown to be weak, both at trial and in the CTIX press response(s). Its effects should have been nullified a long time ago if what you refer to as numerous positive trial results were perceived as such by an adequate number of investors. They haven't been.
News 
Market Data 
Discover 
